Skyai, Inc. quarterly report, Q3 FY2025

Business Context and Reporting Period

Company: Sharps Technology, Inc. (STSS)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Historically a medical device manufacturer, the Company underwent a strategic pivot in August 2025. It adopted a digital asset treasury strategy focused on accumulating Solana (SOL) and ceased manufacturing operations to function primarily as a distributor. The Company now operates two segments: Medical Device Packaging and Digital Asset Treasury.

Key Financial Metrics

Metric Q3 2025 (3 Months) YTD 2025 (9 Months) YTD 2024 (9 Months)
Total Revenue $2.29 Million $2.51 Million $0
(Product Revenue) $83,622 $306,344 $0
(Staking Revenue) $2.21 Million $2.21 Million $0
Net Loss $(105.33) Million $(99.85) Million $(4.77) Million
Net Loss Per Share (Basic/Diluted) $(4.33) $(11.79) $(1,358.58)
Cash and Cash Equivalents $10.52 Million $10.52 Million $2.47 Million (End of Period)
Digital Assets (SOL & USDC) $418.90 Million $418.90 Million $0
Total Assets $443.96 Million $443.96 Million $7.31 Million
Total Liabilities $10.75 Million $10.75 Million $5.32 Million
Working Capital $29.05 Million $29.05 Million $(2.01) Million Deficiency

Material Changes vs. Prior Period

  • Strategic Pivot: The Company shifted from a manufacturing model to a digital asset treasury model in August 2025. This resulted in the recognition of $2.21 million in staking revenue and a $15.50 million unrealized gain on digital assets for the quarter.
  • Revenue Composition: Product revenue remains negligible ($83,622 for Q3) compared to the new staking revenue stream. The Company recorded a gross loss on product sales due to inventory reserves ($924,010) established to terminate manufacturing.
  • Explosive Expense Growth: Selling, General, and Administrative (SG&A) expenses surged to $110.72 million in Q3 2025 from $1.87 million in Q3 2024. This increase is primarily driven by a $101.33 million non-cash stock-based compensation charge related to warrants issued to a strategic advisor.
  • Asset Impairment: The Company recorded a $7.50 million impairment of long-lived fixed assets associated with the pending sale of its Hungarian subsidiary (Safegard Medical Kft).
  • Liquidity Transformation: Total assets increased from $7.31 million (Dec 2024) to $443.96 million (Sep 2025), driven by a $411 million capital raise in August 2025 (cash, stablecoins, and SOL).

Guidance, Outlook, and Risks

  • Capital Raise: In August 2025, the Company completed a $411 million offering (Cash and Cryptocurrency Securities Purchase Agreements), receiving net proceeds of $403 million. This included cash, USDC, and SOL tokens.
  • Share Repurchase: In October 2025 (Subsequent Event), the Board approved a $100 million share repurchase program.
  • Settlement of Litigation: In October 2025, the Company settled outstanding litigation with Barry Berler and Plastomold Industries. As part of the settlement, the Company transferred its Hungarian subsidiary and related assets to the counterparties.
  • Key Risks:
    • Digital Asset Volatility: The Company holds ~$404 million in SOL. A 10% fluctuation in SOL price would impact pre-tax income by approximately $40.4 million.
    • Concentration Risk: The treasury strategy is heavily concentrated in a single digital asset (SOL).
    • Related Party Transactions: Significant consulting fees ($10.7 million annual commitment) and warrant issuances were made to entities controlled by the brother of the Chief Investment Officer.

Investor Verification Checklist

  • Valuation of Digital Assets: Verify the fair value methodology for locked vs. liquid SOL and the 10% discount applied to locked tokens.
  • Stock-Based Compensation: Review the $101.33 million warrant issuance to the Strategic Advisor (Sol Markets) and the related party nature of this transaction.
  • Manufacturing Exit: Confirm the status of the Hungarian subsidiary spin-off and the finality of the manufacturing termination.
  • Derivative Exposure: Assess the $7.63 million margin loan and derivative liabilities ($446,876) used to manage SOL exposure.
  • Going Concern: Note that management asserts the new liquidity position removes substantial doubt regarding the Company's ability to continue as a going concern.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.